Table 1 Baseline characteristics of study patients stratified by neurological outcome
Variables | All patients (n = 402) | Patients with favourable neurological outcome at hospital discharge (n = 70) | Patients without favourable neurological outcome at hospital discharge (n = 332) | p value |
|---|---|---|---|---|
Age, y (SDa) | 65.4 (15.7) | 62.5 (14.0) | 66.1 (16.0) | 0.03 |
Male, n (%) | 243 (60.4) | 52 (74.3) | 191 (57.5) | 0.01 |
Comorbidities, n (%) | ||||
 Heart failure | 109 (27.1) | 25 (35.7) | 84 (25.3) | 0.08 |
 Myocardial infarction | 60 (14.9) | 19 (27.1) | 41 (12.3) | 0.003 |
 Arrhythmia | 91 (22.6) | 17 (24.3) | 74 (22.3) | 0.75 |
 Hypotension | 111 (27.6) | 17 (24.3) | 94 (28.3) | 0.56 |
 Respiratory insufficiency | 272 (67.7) | 40 (57.1) | 232 (69.9) | 0.05 |
 Renal insufficiency | 179 (44.5) | 22 (31.4) | 157 (47.3) | 0.02 |
 Hepatic insufficiency | 71 (17.7) | 7 (10) | 64 (19.3) | 0.08 |
 Metabolic or electrolyte abnormality | 83 (20.6) | 10 (14.3) | 73 (22.0) | 0.19 |
 Diabetes mellitus | 157 (39.1) | 31 (44.3) | 126 (38.0) | 0.35 |
 Baseline evidence of motor, cognitive, or functional deficits | 177 (44.0) | 23 (32.9) | 154 (46.4) | 0.05 |
 Acute stroke | 22 (5.5) | 2 (2.9) | 20 (6.0) | 0.39 |
 Favourable neurological status 24 h before cardiac arrest | 215 (53.5) | 50 (71.4) | 165 (49.7) | <0.001 |
 Bacteraemia | 31 (7.7) | 2 (2.9) | 29 (8.7) | 0.14 |
 Metastatic cancer or any blood borne malignancy | 65 (16.2) | 1 (1.4) | 64 (19.3) | <0.001 |